This past week was full of incredible federal and legislative actions in the mission to protect children from the harms of gender ideology.
Federal Action to Protect Children: U.S. Department of Health and Human Services leaders unveiled a plan to restore ethical, evidence-based pediatric care and announced action to prohibit hospitals from performing sex-rejecting procedures on minors.
House Passes Do No Harm Act: The U.S. House of Representatives passed the Do No Harm in Medicaid Act to stop taxpayer dollars from funding medically unnecessary and irreversible procedures on children.
Citizen Petition Urges FDA Accountability: A formal petition calls on the U.S. Food and Drug Administration to hold a public hearing and review the off-label use of estrogen in young males.
Warm wishes this holiday season,
The Biological Integrity Team
The American College of Pediatricians
HHS Acts to Prohibit Hospitals from Performing Sex-Rejecting Procedures
Last Thursday, leaders from HHS and NIH hosted “Protecting Children,” an impressive panel outlining major goals and action plans to restore safe, ethical, and evidence-based practices in pediatric medicine. HHS has also announced it will take action to prohibit hospitals from performing sex-rejecting procedures on children.
Dr. Jill Simons, Executive Director of ACPeds, issued the following statement in response:
“The American College of Pediatricians (ACPeds) applauds this action by HHS as a necessary step in preventing hospitals across the U.S. from performing harmful chemical and surgical interventions on minors. These procedures are irreversible, unethical, and ideologically driven.”
House Passes Do No Harm in Medicaid Act
Last week, the U.S. House of Representatives passed the Do No Harm in Medicaid Act, advanced by the House Energy and Commerce Committee, to stop federal Medicaid dollars from funding experimental procedures on minors.
The bill aims to ensure taxpayer funds are directed toward legitimate, evidence-based medical care and not irreversible interventions on children. This measure strengthens the integrity of Medicaid while prioritizing the safety and well-being of minors.
Citizen Petition Urging FDA to Stop Off-Label Use of Estrogen in Young Males
Last Wednesday, a citizen petition was submitted to FDA calling for regulatory review, public hearings, and potential safety warnings on the off-label use of estrogen in young males for the treatment of sexual identity disorder.
The petition highlights an array of serious medical risks associated with administering estrogen to males in the name of “hormone therapy.” This step seeks accountability and transparency from the FDA and is necessary to protect minors from harmful, irreversible drugs.
